Trinity Biotech (NASDAQ:TRIB) Posts Quarterly Earnings Results

Trinity Biotech (NASDAQ:TRIB) issued its earnings results on Tuesday. The company reported ($0.23) EPS for the quarter, Zacks reports.

Trinity Biotech Price Performance

TRIB traded down $0.06 during trading on Tuesday, reaching $0.62. 468,821 shares of the stock were exchanged, compared to its average volume of 199,786. The company has a market capitalization of $2.22 million and a price-to-earnings ratio of -0.16. Trinity Biotech has a 1 year low of $0.50 and a 1 year high of $3.44. The business’s 50 day moving average price is $0.65 and its two-hundred day moving average price is $0.75.

Institutional Investors Weigh In On Trinity Biotech

An institutional investor recently raised its position in Trinity Biotech stock. Citadel Advisors LLC boosted its holdings in Trinity Biotech PLC (NASDAQ:TRIB) by 196.1% during the third quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund owned 39,384 shares of the company’s stock after acquiring an additional 26,084 shares during the period. Citadel Advisors LLC owned 1.10% of Trinity Biotech worth $41,000 as of its most recent filing with the Securities and Exchange Commission. Hedge funds and other institutional investors own 78.97% of the company’s stock.

Analyst Upgrades and Downgrades

Separately, Weiss Ratings cut shares of Trinity Biotech from a “sell (d-)” rating to a “sell (e+)” rating in a research note on Friday, May 8th. One equities research analyst has rated the stock with a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat.com, the stock presently has an average rating of “Reduce”.

Trinity Biotech Company Profile

Trinity Biotech plc is a global diagnostic healthcare company headquartered in Bray, Ireland. The firm specializes in the development, manufacture and marketing of in vitro diagnostic products aimed at the detection and management of chronic and infectious diseases. Its offerings are designed to deliver timely and accurate results for a range of healthcare settings, from central laboratories to point?of?care environments.

The company’s product portfolio includes a comprehensive array of assays and instrumentation.